WO1998054212A2 - Das protein des humanen ryanodinrezeptors vom typ 3 sowie dafür kodierende dna-moleküle - Google Patents
Das protein des humanen ryanodinrezeptors vom typ 3 sowie dafür kodierende dna-moleküle Download PDFInfo
- Publication number
- WO1998054212A2 WO1998054212A2 PCT/EP1998/002926 EP9802926W WO9854212A2 WO 1998054212 A2 WO1998054212 A2 WO 1998054212A2 EP 9802926 W EP9802926 W EP 9802926W WO 9854212 A2 WO9854212 A2 WO 9854212A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- polypeptide
- hryr3
- ryr3
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the subject matter of the invention comprises nucleic acids and protein of the human ryanodine receptor of type 3 (hRyR3), chimeric ryanodine receptors with parts of the human receptor as well as methods for the production of these proteins Procedure for the identification of activators or inhibitors of hRyR3
- Cytoplasmic calcium plays an important role in cell activation, neurotransmitter release, muscle contraction and other biological processes. It is increased by the influence of extracellular calcium through voltage-activated and other ion channels and via the calcium release of intracellular preliminary rates.
- intracellular calcium channel There are currently two intracellular calcium channel releases known 1, 4,5-trisphosphate receptors (IP3R) and the ryanodine receptors (RyR)
- IP3R 4,5-trisphosphate receptors
- RyR ryanodine receptors
- RyR1 mainly in skeletal muscle
- RyR2 in cardiac muscle and brain
- RyR3 in brain and smooth muscle
- the RyR3 is also used in non- excitable cells How human T-lymphocytes are expressed
- a role of RyR3 in cell proliferation is postulated (Hakamata, Y et al FEBS Lett, 352 (1994), 206-210).
- RyR3 The function of RyR3 has been the subject of a number of speculations. Although calcium appears to be an important physiological ligand for RyR3, there are some indications that calcium-induced calcium release is a problem differs from that of other RyR It is assumed that an endogenous RyR3 is responsible for the significantly lower calcium sensitivity of the remaining calcium release activity of RyR1 -def ⁇ z ⁇ enten mouse muscle cells. RyR3 has been shown in some cases to be insensitive to caffeine, the main substance used for RyR activation. Since RyR3 is expressed in non-excitable cells that have practically no voltage-activated calcium channels, it seems possible that RyR3 is regulated by other mechanisms than the other RyR RyR3-deficient mouse mutants have an increased locomotive activity.
- the cDNA sequences of RyR1, RyR2 and for the rabbit RyR3 (rRyR3) are already known, while the nuclear acid sequence of RyR3 in humans (hRyR3) has not yet been investigated
- the object of the present invention was to provide the nuclear acid sequence of the human ryanodine receptor of type 3, its amino acid sequence and the determination of structural and physiological peculiarities which distinguish the hRyR3 from all other RyR
- the present invention relates to polypeptides which are characterized in that they have approximately 96% amino acid sequence identity with the rRyR3.
- the present invention comprises the human ryanodine receptor type 3 (hRyR3) with the amino acid sequence according to FIG. 7
- the provided polypeptides and functional derivatives of the hRyR3 now make it possible for the first time to compare the human RyR3 with RyR types of other species and to show differences
- polypeptides according to the invention provided comprise the human RyR3 and its "functional derivatives"
- the term “functional derivative” on which the present invention is based means a component with the biological activity which is essentially similar to the biological activity of the native hRyR3.
- the biological ability relates both to the binding capacity of inhibitors and activators such as Caffeine as well as other physiological ligands of the native receptor as well as the release of intracellular calcium.
- a “functional derivative” also includes parts of the hRyR, the biological properties of which have been changed by fragments of other proteins such as other RyR Example of a chimeric receptor referenced from hRyR3 and rRyR2
- the term “functional derivatives” is intended to include “fragments", variants "and” chemical derivatives ".
- the term” fragment refers to any polypeptide which, when measured on the native receptor, represents a reduced form andhas at least one binding site for a ligand of hRyR
- a “variant” comprises molecules which are essentially derived in function and structure from the native hRyR3, such as, for example, allelic forms. Accordingly, the expression “variant” includes, for example, the molecules which have a similar activity but, for example, a modified amino acid sequence chemical derivative includes additional chemical groups that are normally not part of the molecule. These groups can, for example, increase or decrease the biological activity of the molecule
- One aspect of the present invention relates to chimeric polypeptides, which are characterized in that, in addition to at least one fragment of the human ryanodine receptor of type 3 (hRyR3), they contain at least one further one
- the present invention relates to chimeric polypeptides which are characterized in that, in addition to a fragment of the hRyR3, they contain at least one further fragment from the family of non-human ryanodine receptors
- the present invention relates to chimeras
- Polypeptides which are characterized in that they are next to a fragment of the hRyR3 contain at least one fragment of the rabbit ryanodine receptor type 2 (rRyR2)
- the present invention relates to a chimeric polypeptide, which is characterized in that it contains a fragment of rRyR2 in the region of amino acid 1300 of hRyR3, which gives high sensitivity to calcium or caffeine due to the fact that in comparison to the other RyR types lower calcium release activity of the RyR3, the measurement of the calcium release by known activators such as caffeine is inaccurate or even impossible. This is of great importance for the identification of possible inhibitors or activators of the biological action of the RyR3. It has now surprisingly been found that a chimeric polypeptide, which has an increased calcium or caffeine sensitivity, can be produced from a type 3 RyR fragment and another protein.
- a chimeric polypeptide is made up of a hRyR3 portion and a non-human portion, such as a fragment of Kan ⁇ nchen-rRyR2, presented Surprisingly, it was found that replacing the hRyR3 in the region of amino acid 1300 with part of the rRyR2 gives increased sensitivity to caffeine or calcium. This increased calcium or caffeine sensitivity now enables the person skilled in the art in highly sensitive test systems, for example in vivo cell systems To determine activators and inhibitors by their influence on the intracellular calcium content
- a further aspect of the present invention comprises nucleic acids which code for the polypeptides according to the invention with the biological activity of the native hRyR3.
- Nucleic acids include DNA and also RNA. All nucleic acids according to the invention are distinguished by the fact that they hybridize with a nucleic acid according to the polypeptide sequences according to the invention under stringent conditions Under permanent conditions, DNA sequences hybridize with more than 85% homology and preferably with a homology of more than 90%.
- the invention comprises all the nucleic acid sequences necessary for the recombinant presentation of the polypeptides according to the invention.
- the sequences thus include all additional sequences necessary for the recombinant production of the polypeptides, e.g. Vector and host nucleic acids.
- the present invention provides a method for producing the polypeptides according to the invention, which is characterized in that a nucleic acid according to the invention is introduced into a cell or a cell-free in vitro translation system.
- the method is further characterized in that the nucleic acid can be part of an expression vector.
- Appropriate usable expression vectors, cells, cell-free in vitro translation systems and the necessary methods for producing the polypeptides are familiar to the person skilled in the field of molecular biology.
- a still further aspect of the present invention relates to the use of the polypeptides and / or nucleic acids according to the invention as a pharmaceutical or as part of a pharmaceutical, or the use of the polypeptides and / or nucleic acids for the production of a pharmaceutical for the treatment of hRyR3-associated diseases.
- the invention also encompasses nucleic acids as a pharmaceutical or as a component of a pharmaceutical which is complementary to the nucleic acid of one of the proteins according to the invention.
- Such complementary nucleic acids are known to the person skilled in the art under the name “antisense” nucleic acids and their therapeutic importance is familiar to the person skilled in the art.
- An additional aspect of the present invention relates to methods for the detection of the polypeptides according to the invention and their nucleic acids.
- polypeptides according to the invention now make it possible for the first time to provide highly specific immunological methods for detecting these polypeptides in low concentrations.
- the invention relates to methods for the detection of the invention O
- polypeptides which are characterized in that the polypeptide is detected immunologically, immunological methods such as e.g. the production, purification and use of monoclonal and polyclonal antibodies for the quantitative and qualitative highly specific detection of peptides are known to the person skilled in the art from the prior art.
- the invention also includes the molecular biological detection of the nucleic acid coding for the polypeptides. Molecular biological evidence is well known to those skilled in the field of molecular biology and includes, among others. Hybridization and PCR (polymerase chain reaction) methods.
- the method for detecting a nucleic acid according to the invention is characterized in that a nucleic acid complementary to this nucleic acid or to a part of this nucleic acid is used for hybridization.
- Another aspect of the present invention includes the use of the polypeptides and / or nucleic acids provided for determining possible inhibitors and activators of hRyR3. Accordingly, the present invention also encompasses methods for the in vitro and / or in vivo identification of activators and / or inhibitors of hRyR3, which are characterized in that a nucleic acid according to the invention is introduced and expressed in a cell or a cell-free system, the expression product is exposed to a potential inhibitor or activator and the ion flow mediated by the expression product is measured.
- the term in vitro refers to cell-free, the term in vivo to cell systems.
- activators and / or inhibitors are introduced into membrane-enclosed cell-free systems which express the polypeptides according to the invention and, after adding potential activators and inhibitors, the change in the ion concentration in the membrane-enclosed space is determined.
- the present invention provides for the first time, by expressing the polypeptides according to the invention in RyR-deficient cells, a system in vivo that enables activators and inhibitors of hRyR3 to be determined in isolated cells. Methods for the expression of polypeptides in cells and cell-free systems using the corresponding nucleic acid are known to the person skilled in the art from the prior art.
- the invention in a very special embodiment also includes the injection of the polypeptides into these cells and systems for the identification of inhibitors and / or activators according to the methods described above. Potential inhibitors and activators are identified by demonstrating the changed influence of the expression product on the cell.
- the changed influence of the peptide or expression product can be measured by the mediated ion flow or by the change in the ion concentration in the membrane-enclosed space. Generally, the concentration of intracellular calcium ions is measured.
- An exemplary experimental setup of such a method for determining activators or inhibitors consists, for example, of a hRyR3-expressing cell system or cell-free system which has no or only little endogenous ryanodine receptor activity, with a measurable change in the ion concentration within the cell system after the addition of potential inhibitors or activators or the membrane-enclosed space is determined.
- Systems for determining activators and inhibitors are already known for the RyR1 and RyR2.
- the present invention comprises the detection of the polypeptides according to the invention and / or the hRyR3, for the diagnosis of pathologically changed tissues.
- the polypeptides and / or nucleic acids according to the invention can be used to produce a diagnostic agent which enables a method for diagnosing pathological conditions, such as overexpression or the lack of hRyR3 in tissues, to be carried out, which is characterized in that is that the presence, overexpression or deficiency of one of the polypeptides according to the invention is detected.
- a very special embodiment of the present invention relates to methods for diagnosing pathological conditions through the immunological detection of the polypeptides according to the invention by antibody binding.
- a person skilled in the art understands a pathological condition of a tissue to be any deviation from the normal physiological conditions as is evident in the majority of clearly healthy tissue.
- the overexpression or the deficiency of the polypeptides according to the invention in tissues and cells can be determined both by immunological methods and by the molecular-biological detection of the nucleic acid coding for the polypeptides.
- the present invention therefore comprises methods for diagnosing pathological conditions, which are characterized in that the nucleic acid coding for the polypeptide according to the invention is detected.
- Appropriate Molecular biological evidence is well known to the person skilled in the field of molecular biology and includes, among other things, hybridization methods and PCR (polymerase chain reaction) methods.
- the present invention allows the person skilled in the art for the first time to display highly specific hRyR3 hybridization probes with which the presence or lack of nucleic acids of hRyR3 in tissues can be detected.
- Highly specific probes can now be developed for the detection of hRyR3 by PCR ("polymerase chain reaction").
- pathological conditions in tissues can be detected by molecular biological methods
- the sequence and molecular-physiological characterization of the cDNA sequence of the native peptide of the hRyR3 according to the invention is disclosed below.
- the cDNA sequence was identified and characterized by molecular biological hybridization methods known to the person skilled in the art and subsequent sequencing of several overlapping cDNA clones (see Example 1)
- the primary structure of the native polypeptide according to the invention has been determined by comparing the corresponding reading frame of the amino acid sequence of the rabbit RyR3 (Hakamata Y et al FEBS Lett 312! (1992), 229-235).
- the amino acid sequence of the native polypeptide is 4866 amino acids long and corresponds to a molecular weight of 551046 Since FIG.
- the amino acid sequence of the hRyR3 derived from the cDNA shows the amino acid sequence of the hRyR3 derived from the cDNA.
- the nucleotide sequence GAGCCATGG in the region around the translational initiation codon agrees well with the consensus initiation sequence CCA (G) CCATGG (Kozack M Nucleic Acids Res 12 (1984), 857-872)
- the 3 non-coding region is 873 nucleotides long (without the poly (da) region), the polyadenylation signal AATAAA (Goeddel, DV et al Nature 290 (1981), 20- 26) is located 21 nucleotides above the poly (da) region.
- the amino acid sequence comparison shows in each case over 90% (approx.
- hRyR3 / rRyR3 identity between hRyR3 / rRyR3, or over 60% identity between hRyR3 / rRyR2 (approx. 69%) and hRyR3 / RyR1 (approx. 67%)
- the hydropathicity profile of the hRyR3 is comparable to that of rabbit rRyR3, rRyR2, rRyR1 and human RyR1 insofar as there is no hydrophobic amino terminal sequence indicating a signal sequence and that the remaining areas are mainly hydrophilic and that there are four strongly hydrophobic segments (named M1, M2, M3 and M4) in the carboxy-terminal end.
- the carboxy-terminal region in the region of the M3 and M4 segments Es is particularly well preserved in all RyR there are also clear differences.
- RyR2 has an EF hand consensus sequence in this region (Moncrief, NDJ Mol Evol 30 (1990) , 522-562) (in the region of amino acids 1336-1347) and a nucleotide binding consensus sequence GXGXXG (Wierenga, RK Nature 302 (1983), 842-844) (amino acid residues 1324-1329) (Nakai, J et al FEBS Lett 271 (1990) , 169-177) Furthermore, the region immediately in front of the M1 segment differs in that there is a divergence between hRyR3 and rRyR3.
- the hRyR3 has four repeating sequences in two tandem pairs (amino acid residues 841 -954, 955-1070, 2600-271 1 and 2712-2791) Potential ligand binding sites can be determined via proposed consensus amino acid sequences. A sequence similar to the motif of the EF hand (Moncrief, NDJ Mol Evol 30 (1990), 522-562) can be seen in amino acid residues 3928-3939, a region which is also in r RyR3, RyR2 and RyR1 is relatively well preserved.
- amino acids 3465-3476 consisting of an amphipathic helix with two groups of positive charges that are separated by a hydrophobic region (Blumenthal, DK Proc Natl Acad Sei USA) 82 (1985), 3187-3191), particularly well preserved in rRyR3, rRyR2 and rRyR1.
- the molecule has four copies of the nucleotide binding consensus sequence GXGXXG (Wierenga, RK Nature 302 (1983), 842-844) (amino acid residues 697-702, 699 -704, 1 135-1 140, 2235-2240 and 2524-2529), of which the amino acids 2235-2240 are well preserved in rRyR3, rRyR2 and rRyR3.
- the functional analysis of the RyR3 has so far not been able to show any direct evidence of its function as a calcium release channel.
- the functional recombinant expression of the hRyR3 by mouse myotubes without the skeletal muscle isoform of the RyR (Nakai, J et al Nature 380 (1996), 72-75).
- FIG. 2B shows a caffeine reaction of the chimeric RyR expressed in dyspedic myotubes.
- non-injected dyspedic myotubes show no reaction to 1 mM caffeine (Fig.
- a very special embodiment of the present invention relates to the detection of hRyR3 in tissues. This is possible with hRyR3-specific probes and the Northem blot analysis of mRNA from various human tissues. It can be shown that, although in the whole brain only a weak signal for RNA can be observed, an approximately 16 kb RNA piece with hRyR cDNA samples in a relatively large amount in limited brain areas such as the caudate nucleus, amygdala and hippocampus and in somewhat smaller amounts in the corpus callosum, substantia nigra and thalamus (FIG. 3) hybridized The limited distribution of RyR3 in the human brain allows the following assumptions.
- the RyR is also directly coupled to L-type calcium channels in the brain. While P-type and other types of calcium channels are exposed throughout the brain, the R -Type calcium channel only in the very limited regions of the brain, such as in the caudate nucleus and hippocampus (Nndom e, T et al FEBS Lett 308 (1992), 7-13) With a similar distribution of R-type calcium channel and RyR3 it is likely that the RyR3 can interact directly with the R-type calcium channel in these regions Regions of the RyR3 expression also roughly correspond to the areas in which the "delayed neuronal death" after hypoxia takes place in the brain, it is likely that this type of RyR plays an important role in pathological conditions. The increased locomotor activity of RyR3-deficient mice reflects this distribution of the RyR3
- RNA species that hybridizes with hRyR3 cDNA samples also succeeds outside the brain in skeletal muscle (FIG. 4).
- the size of the RNA species of these tissues of approximately 16 kb corresponds to the species in the brain
- a weak signal suggests the existence of RyR3 mRNA in heart tissue.
- the distribution of mRNA outside the brain differs from that of rabbits because the RyR3 expression in rabbit skeletal muscle is undetectable. Due to the high content of RyR1 mRNA in skeletal muscle there is a Small contribution due to cross-hybridization of RyR3 samples with RyR1 mRNA not excluded.
- the RyR3 expression varies between the species and that the RyR3 expression is more pronounced in human skeletal muscle than in other species. It is known that an acute increase in intracellular calcium in human Skeletal muscle triggers malignant hyperthermia (MH) (MacLennan, DH and Philips, MS Science 256 (1992), 789-794) although MH is associated with mutations in RyR1 (Gillard, EF et al Genomics 1_ (1991), 751-755) , only 5% of the MH trap shows a mutation in position 614 of the RyR1 gene by Arg to Cys substitution. The abundant expression of RyR3 in human skeletal muscle makes it very likely that RyR3 is involved in variant forms of MH. There is also the possibility that the RyR3 could also be involved in other disorders of intracellular calcium regulation
- the hRyR3 is present in pathological conditions in humans and can be detected in pathologically modified tissues.
- tissue-specific distribution of the RyR3 in human Brain is related to the cell-specific calcium regulation in the production.
- RyR3-mRNA is expressed in several human cell lines (Fig. 5). Abundant expression can be found in U373, a cell from malignant astrocytoma, a weak expression in IMR-32 from malignant neuroblastoma cells and an even lower expression in H4 from malignant neurogoma cells.
- the RyR2 expression in IMR-32 no other RyR types are detectable in U373 or H4.
- Oligo (dT) and random primer cDNA libraries from human brain (nucleus caudatus) from Clontech (USA) were used, which were isolated from poly (A) + RNA and cloned into ⁇ gt10 phages.
- the interfaces of the residual endonucleases are identified by numbers (in brackets ), which describe the 5 ' terminal nucleotide resulting from the cleavage; the nucleotide residues are numbered in the 5 ' -3 ' direction, starting with the first residue of the ATG Tnplet, which encodes the methionine which is likely to initiate.
- RNA (A) + RNA (Clontech) from the human brain was incubated together with RNase H'Reverse Transk ⁇ ptase from Moloney 's murine leukemia virus (Gibco BRL) with a random spammer.
- the first synthesized cDNA- Strand was according to the manufacturer's instructions (TaKaRa LA PCR Kit) using a DNA Thermal Cycler's (Perkin-Elmer Corp) amplified After a hot start (1 min, 94 ° C) the samples were 30 cycles of 20 s at 98 ° C and Exposed for 5 min at 68 ° C.
- Primer pairs for phBRR501 were phBRR51 - and ph95R950 for phBRR51 - and phpRR5150 for phBRR5150 were each 25-nucleotiddohgomers of bases 2949-2973 (upper polymer, AGTGGATAAACTTGCAGAAAATGCA) and 3495-3519 (lower primer, TGGGGAGCTGCTGATCACCAATAAA) for phBRR51 - Synthetic 20-nucleotide OHGomers of bases 11369-1 1388 (upper primer, TTGATGAATCTGGACAGCAC) and 12353-12372 (lower primer, ACGTGTTAGAAATTGCGGGT) of the phBRR79 and phBRR91 clones.
- the entire protein coding sequence of human RyR3 was cloned into the EcoRI / NotI site of pCI-neo (Promega) and resulted in hNRR9.
- the cDNA insert was constructed from the following fragments EcoRI (Vector) / Mrol (1232) obtained from lhBRR22, Mrol (1232) / H ⁇ ndlll (2956) from lhBRR61, H ⁇ ndlli (2956) / Bcll (3506) from lhBRR501,
- Caffeine was injected by local injection a "w ⁇ de-t ⁇ pped" pipette (10-50 mm diameter) applied.
- Normal rodent-Ringer solution of the following composition was used as a washing solution (mM) 145 NaCl, 5 KCI, 2 CaC-2, 1 MgCl 2 , 10 HEPES, pH 7 4 adjusted with NaOH.
- the temperature was 20-22 ° C
- MTN Multiple Tissue Northern
- Each lane of the MTN blots contains approximately 2 ⁇ g poly (A) + RNA from the following brain regions amygdala, nucleus caudatus, corpus callosum , Hippocampus, whole brain, substantia nigra, subthalamic nucleus and thalamus
- Each lane of the other MTN blot contains approximately 2 mg poly (A) + RNA of the following human tissues heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas
- Each lane of the third blot contains approximately 20 mg of total RNA from the following human cell lines (Hakamata Y, et al FEBS Lett 312 (1992), 229-235) SK-N-MC (derived from original neuroblastoma), IMR-32 (neuroblastoma), HEL-299 (pulmonary fibroblast), H4 (
- the sample was mixed with the Klenow fragment of DNA polymerase and [ 32 P] dCTP (Feinberg, AP & Vogelstein, B Anal Biochem 132 (1983), 6-13) by random oligonucleotide polymer.
- the blot was hybridized at 42 ° C. and washed three times with 0.3 ⁇ SSC, 0.1% SDS at 50 ° C. 4 Luminescence determination
- the luminescence determination was carried out (Maeda, A et al, Anal Biochem 242, (1996), 58-66).
- the cells (1 ⁇ 10 5 cells / vessel) were included in the solution of the calcium assay of the following composition transfers (mM) 140 NaCl, 5 KCI, 1, 5 MgCl 2 , 2.5 CaCl 2 , 5 glucose and 10 HEPES, pH 7.4 adjusted with NaOH, including 2.5 mM coelenterazine, the intermediate substrate of Aequo ⁇ n, and incubated at 37 ° C for 6 h
- the system for luminescence measurement consisted of the spectrofluorometer CAF-1 10 (Jasco) (Hakamata Y et al, FEBS Lett 352, (1994), 206-210), which with a Luminescence unit PL-03 (Jasco)
- the mobilization of intracellular calcium was induced by injection of caffeine in a final concentration of 10 mM and ryanodine receptor of 100
- FIG. 3 shows the distribution of human RyR3 in human brain by Northern blot analysis of different regions of the brain with cDNA samples for human RyR3 mRNAs. 2 mg poly (A) + RNA were used in each case. Autoradiography was carried out at -70 ° C for 7 days with an intensifying screen
- FIG. 5 shows the distribution of human RyR3 in human cell lines by Northern blot analysis of human RyR mRNA expression in rabbit skeletal muscle, rabbit heart, rabbit whole brain and human cell lines such as neuroblastoma (SK-N-MC, IMR-32), lung fibroblasts ( HEL-299), Neurog oma (H4), Neuroblastoma (SK-N-SH), embryonic kidney cells (HEK293) and astrocytoma (U373) with cDNA probes for human RyR3 mRNAs. 20 mg total RNA were used in each case. Autoradiography was carried out at -70 ° C for 4 days with an intensifying screen
- the inconsistent reaction is probably not due to the fact that the ryanodine receptor does not reach the site of action as described recently (Penner, R et al, FEBS Lett 259, (1989), 217-221)
- the time of adding caffeine and ryanodine receptor is marked by small bars
- Figure 8 shows the DNA sequence of the human ryanodine receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/424,783 US6780608B1 (en) | 1997-05-28 | 1998-05-18 | Human type 3 ryanodine receptor protein and DNA molecules coding therefor |
EP98929337A EP0984986A2 (de) | 1997-05-28 | 1998-05-18 | Das protein des humanen ryanodinrezeptors vom typ 3 sowie dafür kodierende dna-moleküle |
CA002291960A CA2291960A1 (en) | 1997-05-28 | 1998-05-18 | Human type 3 ryanodine receptor protein and dna molecules coding therefor |
JP50018299A JP2002504813A (ja) | 1997-05-28 | 1998-05-18 | 型3ヒトリアノジン受容体のタンパク質及びそれをコードするdna分子 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19722317.6 | 1997-05-28 | ||
DE19722317A DE19722317C1 (de) | 1997-05-28 | 1997-05-28 | Das Protein des humanen Ryanodinrezeptors vom Typ 3 sowie dafür kodierende DNA-Moleküle |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998054212A2 true WO1998054212A2 (de) | 1998-12-03 |
WO1998054212A3 WO1998054212A3 (de) | 1999-03-11 |
Family
ID=7830730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/002926 WO1998054212A2 (de) | 1997-05-28 | 1998-05-18 | Das protein des humanen ryanodinrezeptors vom typ 3 sowie dafür kodierende dna-moleküle |
Country Status (6)
Country | Link |
---|---|
US (1) | US6780608B1 (de) |
EP (1) | EP0984986A2 (de) |
JP (1) | JP2002504813A (de) |
CA (1) | CA2291960A1 (de) |
DE (1) | DE19722317C1 (de) |
WO (1) | WO1998054212A2 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO314277B1 (no) * | 1999-06-08 | 2003-02-24 | Unifob Stiftelsen Universitets | Deteksjon av ryanodin-reseptor-antistoff |
US8022058B2 (en) * | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20070196856A1 (en) * | 2006-02-23 | 2007-08-23 | Allergan, Inc. | Methods of determining activity of ryanodine receptor modulators |
WO2007143112A2 (en) * | 2006-06-02 | 2007-12-13 | The Trustees Of Columbia University In The City Of New York | Methods for diagnosing disorders and diseases associated with ryanodine receptors and methods for identifying compounds that affect ryanodine receptors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004328A1 (en) * | 1989-09-25 | 1991-04-04 | The University Of Toronto Innovations Foundation | Diagnosis for malignant hyperthermia |
-
1997
- 1997-05-28 DE DE19722317A patent/DE19722317C1/de not_active Expired - Fee Related
-
1998
- 1998-05-18 JP JP50018299A patent/JP2002504813A/ja not_active Ceased
- 1998-05-18 EP EP98929337A patent/EP0984986A2/de not_active Withdrawn
- 1998-05-18 US US09/424,783 patent/US6780608B1/en not_active Expired - Lifetime
- 1998-05-18 WO PCT/EP1998/002926 patent/WO1998054212A2/de not_active Application Discontinuation
- 1998-05-18 CA CA002291960A patent/CA2291960A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004328A1 (en) * | 1989-09-25 | 1991-04-04 | The University Of Toronto Innovations Foundation | Diagnosis for malignant hyperthermia |
Non-Patent Citations (3)
Title |
---|
HAKAMATA, Y. et al. Involve- ment of the brain type of ryanodine receptor in T-cell proliferation. FEBS Letters, 1994, Band 352, Seiten 206- 210, insbesondere der ganze Artikel (in der Beschreibung ge- nannt), XP002900281 * |
HAKAMATA, Y. et al. Primary structure and distribution of a novel ryanodine re- ceptor/calcium release channel from rabbit brain. FEBS Letters, November 1992, Band 312, Seiten 229-235, insbesondere der ganze Ar- tikel (in der Beschreibung ge- nannt), XP002900282 * |
MCPHERSON, P.S. et al. So- lubilization and Biochemical Characterization of the High Affinity (3H)Ryanodine Re- ceptor from Rabbit Brain Membranes. The Journal of Biological Chemistry, October 1990, Band 265, Nr. 29, Seiten 18454-18460, insbe- sondere der ganze Artikel, XP002900283 * |
Also Published As
Publication number | Publication date |
---|---|
US6780608B1 (en) | 2004-08-24 |
WO1998054212A3 (de) | 1999-03-11 |
DE19722317C1 (de) | 1998-10-08 |
CA2291960A1 (en) | 1998-12-03 |
EP0984986A2 (de) | 2000-03-15 |
JP2002504813A (ja) | 2002-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69836131T2 (de) | Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen | |
DE19964269B4 (de) | Verfahren zur Detektion des Proliferationspotentials von Zellen | |
DE69731834T2 (de) | Agouti verwandtes gen | |
DE69838334T2 (de) | Kdr, ein menschlicher tyrosin kinase rezeptor | |
DE69838905T2 (de) | Transkriptionsfaktor islet-brain 1 (ib1) | |
DE69834432T2 (de) | G-protein gekoppelter rezeptor | |
DE69634412T3 (de) | Regulierte gene und ihre verwendungen | |
DE69839123T2 (de) | Prostattumor polynukleotid- und antigenzusammensetzungen | |
DE69926764T2 (de) | Methoden zur bestimmung von komponenten zur modulation des körpergewichts | |
DE69534351T2 (de) | Motorneuronlebenserhaltungsgen: ein Gen für spinale Muskelatrophie | |
DE69837085T2 (de) | Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen | |
DE69334146T2 (de) | Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung | |
DE69837267T2 (de) | Kcnq kaliumkanäle und verfahren zur deren modulierung | |
DE69819505T2 (de) | Mit smad wechselwirkende polypeptide und verwendungen davon | |
DE69332798T2 (de) | Ikaros: ein regulatorisches gen bei der t-zell differenzierung | |
DE19722317C1 (de) | Das Protein des humanen Ryanodinrezeptors vom Typ 3 sowie dafür kodierende DNA-Moleküle | |
DE69131421T3 (de) | Für den rezeptor des granulozytenkolonie stimulierenden faktors kodierende dns | |
DE69633131T2 (de) | Rezeptor des y-y5 neuropeptids | |
DE69535590T2 (de) | Für den bradykinin-b1-rezeptor kodierende dna | |
DE60307061T2 (de) | Verfahren zum nachweis von liganden des leptinrezeptors | |
DE69924120T2 (de) | Für ataxin-2-bindende proteine kodierende nukleinsäure, damit verwandten produkten und verfahren zur deren anwendung | |
DE60036548T2 (de) | Neue kalium-kanäle und dafür kodierende gene | |
DE69734890T2 (de) | Rdgb-proteine | |
DE69936733T2 (de) | Vaskulärer endothelialer wachstumsfaktor x | |
DE69737561T2 (de) | Klonierte rezeptoren des glukagon-ähnlichen peptids-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998929337 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/010809 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2291960 Country of ref document: CA Ref country code: CA Ref document number: 2291960 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1999 500182 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09424783 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998929337 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998929337 Country of ref document: EP |